ACIP Endorses RSV Vaccine for At-Risk Adults 50 and Up

CDC Advisers Recommend Making RSV Vaccines Available to Younger Age Group

Advisers to the Centers for Disease Control and Prevention on April 16 recommended that the agency expand the availability of vaccines against the respiratory syncytial virus, or RSV. Adults with at least one risk factor for RSV should be able to receive a vaccine, the Advisory Committee on Immunization Practices said in a 14–0 vote, with one member abstaining. “What’s swaying me is there clearly are people in that 50 to 59 year sort of age grou…

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

CDC panel backs broader use of RSV shots

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

Vaccine advisory panel recommends expanded RSV use, and two new vaccines

ACIP voted Wednesday to recommend lowering the age at which adults can get a vaccine against respiratory syncytial virus.

ACIP Endorses RSV Vaccine for At-Risk Adults 50 and Up

(MedPage Today) -- The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that high-risk patients ages 50 to 59 be vaccinated for respiratory syncytial virus (RSV), and also added...

AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

PHILADELPHIA--(BUSINESS WIRE)--Apr 16, 2025-